BackgroundSepsis-associated encephalopathy (SAE) is a severe complication with high mortality. The effect of ondansetron (OND) on the outcomes of SAE patients remains unclear.MethodsUsing the Intensive Care IV Medical Information Mart (MIMIC-IV) database, we identified 7,829 SAE patients, comprising an OND group (n = 3,954) and a non-OND group (n = 3,875). Propensity score matching (PSM) was employed to generate 3,066 pairs of matches in a 1:1 ratio. The primary outcomes encompassed the 30-day, 90-day, 180-day, and 360-day mortality rates. The secondary outcomes included the duration of ICU stay, the duration of mechanical ventilation, and the incidence of QT interval prolongation. Survival analysis was conducted using Cox proportional hazards regression and Kaplan-Meier curves. Sensitivity analyses, including E-value assessment and a landmark analysis at 5 days to address immortal time bias, were performed. Subgroup analysis was applied to investigate potential differences in the effect of OND treatment on clinical outcomes among various subgroups.ResultFollowing PSM, the baseline characteristics were well-balanced between the cohorts. The group receiving OND demonstrated significantly lower mortality rates at 30 days (HR = 0.64, 95% CI [0.56–0.73], *p*<0.001), 90 days (HR = 0.75, 95% CI [0.66–0.84], *p*<0.001), 180 days (HR = 0.78, 95% CI [0.69–0.88], *p*<0.001), and 360 days (HR = 0.76, 95% CI [0.67–0.85], *p*<0.001) compared with the non-OND group. The landmark sensitivity analysis confirmed the robustness of this survival benefit (p < 0.001). Kaplan-Meier analysis confirmed a significant survival advantage for OND-treated patients with SAE. After matching, the OND group was associated with significantly shorter durations of ICU stay and mechanical ventilation compared with the non-OND group; however, the incidence of QT interval prolongation did not differ significantly between the two groups. Subgroup analysis indicated that adult patients younger than 65 years may derive greater survival benefit from OND treatment.ConclusionIn SAE patients, OND use is associated with significantly lower short- and long-term mortality, suggesting its potential as an adjunct therapy. However, further prospective randomized controlled trials are warranted to validate these results.

BackgroundThe use of ondansetron (OND) has proven to be beneficial in the prognosis of critically ill patients. However, whether early OND use has a benefit in acute respiratory distress syndrome (ARDS) patients on mechanical ventilation (MV) is unknown. This study aimed to investigate the association of the early use of OND with the risk of 30-day mortality in ARDS patients who received MV support.MethodsThis cohort study retrospectively extracted patients with ARDS from the Medical Information Mart for Intensive Care (MIMIC)-IV database from 2008 to 2019. All potential covariates were incorporated in the univariate and multivariable Cox proportional hazard models with a two-way stepwise regression analysis. Univariate and multivariable Cox proportional hazard models were used to evaluate the association of early OND use with 30-day mortality before or after the propensity score matching (PSM), with hazard ratios (HRs) and 95% confidence intervals (CIs). Subgroup analysis was performed stratified by age, gender, ARDS grades, ventilator-associated pneumonia (VAP), acute kidney injury (AKI), ventilation time, and vasopressor.ResultsOf the total 6,457 ARDS patients, 1,125 died within 30 days. After PSM, patients who received early OND use had lower odds of 30-day mortality compared with those who did not (HR =0.77, 95% CI: 0.63–0.94). The low dose of early OND use was associated with a decreased risk of 30-day mortality (HR =0.67, 95% CI: 0.54–0.83). Early OND use was related to lower odds of 30-day mortality of ARDS patients aged ≥65 years (HR =0.54, 95% CI: 0.43–0.67), with females (HR =0.77, 95% CI: 0.61–0.97) or males (HR =0.58, 95% CI: 0.47–0.72), with ARDS grades of mild (HR =0.57, 95% CI: 0.44–0.74), moderate (HR =0.76, 95% CI: 0.60–0.97) or severe (HR =0.69, 95% CI: 0.49–0.98), without VAP (HR =0.64, 95% CI: 0.55–0.76), with AKI (HR =0.62, 95% CI: 0.52–0.74), with short (<43.87 h, HR =0.65, 95% CI: 0.50–0.83) or long (≥43.87 h, HR =0.71, 95% CI: 0.58–0.87) ventilation time, and those who received vasopressor (HR =0.67, 95% CI: 0.56–0.80) or not (HR =0.65, 95% CI: 0.46–0.90).ConclusionsEarly OND use and daily low-dose OND use before MV support were associated with a decreased risk of 30-day mortality, which may be beneficial for the rational use of OND in ARDS patients.

ABSTRACTNausea and vomiting are common and distressing responses to toxins, chemotherapy, and gastrointestinal disturbances. Although antiemetic medications are available, their adverse effects make safer substitutes necessary. In our study, Thymol (THY), a phenolic monoterpene from essential oils, was evaluated for its antiemetic potential using in vivo and in silico methods. In the in vivo study, emesis was induced in 2‐day‐old chicks by oral administration of copper sulfate pentahydrate (50 mg/kg). THY was administered orally at doses of 10, 20, and 40 mg/kg, alone or in combination with standard antiemetics ondansetron (ODN), domperidone (DPD), hyoscine butyl bromide (HYS), and promethazine hydrochloride (PRO). The 20 mg/kg dose (THY‐20) showed the highest efficacy, significantly (p < 0.0001) reducing the number of retches (24.6 ± 2.7; 67.2% reduction) and increasing latency to first retch (52.6 ± 4.2 s; 77.18% increase) compared to the negative control (NC). The THY + ODN combination further enhanced effects (68.53% retch reduction). Molecular docking showed strong binding of THY to 5‐HT3A (−6.4 kcal/mol), D2 (−7.1 kcal/mol), M3 (−6.2 kcal/mol), and H1 (−7.1 kcal/mol) receptors, comparable to standard drugs. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling revealed THY's compliance with Lipinski's Rule, high gastrointestinal absorption, blood–brain barrier permeability, and low toxicity risk. The multi‐target binding profile and synergistic potential of THY suggest its promise as a natural, broad‐spectrum antiemetic. Further receptor‐specific studies and trials in chemotherapy‐induced emesis models are recommended to validate its clinical potential.

ABSTRACTBackgroundPreventive measures for postoperative vomiting (POV) in pediatric strabismus surgery are essential. Previous experimental studies have shown the independent antiemetic effects of propofol‐based total intravenous anesthesia (TIVA), dexamethasone (DEX), and ondansetron (OND). However, the real‐world outcomes of POV following the combined use of DEX and OND with propofol/opioid TIVA remain unknown.AimsTo evaluate the longitudinal incidence of POV across three phases of different anesthesia regimens.MethodsThis retrospective observational study was conducted at a single tertiary‐care children's hospital in Japan, including children aged < 18 years who underwent strabismus surgery and had no major comorbidities. The primary outcome was either POV or the use of antiemetics within 24 h or by discharge. Changes in the levels and time‐trend slopes of POV were evaluated using interrupted time series analysis among three phases: (1) sevoflurane with pentazocine, (2) propofol/opioid TIVA with DEX, and (3) propofol/opioid TIVA with DEX and OND.ResultsOf the 2378 children, the POV incidence in Phases 1, 2, and 3 was 109/471 (23.1%), 87/1260 (6.9%), and 28/647 (4.3%), respectively (p < 0.001). A significant level change in POV occurrence was observed from Phase 1 to Phase 2, while no significant level change was found from Phase 2 to Phase 3. The time‐trend changes in POV occurrence showed no significant difference during Phases 2 and 3.ConclusionsReal‐world departmental‐level data showed a decrease in POV occurrence after transitioning from sevoflurane‐based anesthesia with pentazocine to propofol/opioid TIVA with DEX. However, no significant decrease in POV occurrence was found by adding OND to propofol/opioid TIVA with DEX. Further studies are needed to improve the generalizability of evaluating the real‐world antiemetic effect of combining antiemetic medications on propofol/opioid TIVA.

Cost-effectiveness analysis of anaesthesia regimens for paediatric strabismus surgery based on multicentre retrospective cohort data from Japan.

D-pinitol modulates the anti-emetic effects of aprepitant, domperidone, and ondansetron in chicks

Objective: To enhance the solubility of Ondansetron (OND), a wet impregnation approach utilizing porous silica was explored to produce OND-Porous silica composite, and then UV spectrophotometric protocols were employed to evaluate the equilibrium solubility and the loading capacity of the obtained preparation. Methods: Ondansetron and porous silica composites were synthesized via the wet impregnation method and subsequently subjected to evaluation. for their surface morphology and roughness of was carried out using Scanning Electron Microscope (SEM) and Atomic Force Microscopy (AFM), along with X-Ray defrractometry (XRD), Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), and nitrogen adsorption and desorption experiments. Results: The solubility profile of OND was maximized through the development of OS3 composite formula which was 3-4 times higher than the former. Furthermore, the TGA and UV evaluation tests of the enhanced OS3 formula revealed an improvement in the loading capacity of the drug (45-48%). To confirm the successful introduction of OND within the porous of silica structure, XRD analysis exploited, showing a significant alteration in OND amorphousness. The XRD data confirmed a notable reduction in silica surface area (from 68.239 m2/g to 26.226 m2/g), pore width (from 46.13 nm to 1.21 nm), and porous volume (from 1.2229 cm3/g to 0.178 cm3/g) following the loading of drug on silica. Conclusion: It was concluded that this approach was able to introduce a promised method for enhancing the solubility of OND to produce a powder with physical properties, enable to establish further processing steps like tablet compression or even transdermal patch fabrication.

Evaluation of multitarget drugs on the expression of cocaine-induced locomotor sensitization in male rats: A comparative study

Lung cancer, a global mortality leader, often necessitates Video-Assisted Thoracoscopic (VATS) surgery. However, post-operative nausea and vomiting (PONV) is common, highlighting a need for effective management and prevention strategies in this context. A retrospective case–control study at Fujian Medical University Union Hospital evaluated patients undergoing VATS radical resection of lung cancer between May and September 2022. Patients were categorized based on PONV prevention methods, and data encompassing demographics, surgical history, and postoperative adverse events s were analyzed to assess the association between prophylactic protocols and PONV incidence. The Netupitant and Palonosetron Hydrochloride (NEPA) group showed a significant reduction in PONV occurrences post-surgery compared to Ondansetron (ONDA) and Control groups, emphasizing NEPA’s efficacy in alleviating PONV symptoms (P < 0.05). Furthermore, following VATS radical resection of lung cancer, NEPA markedly reduced the intensity of PONV symptoms in patients. Both univariate and multivariate logistic analyses corroborated that NEPA independently reduces PONV risk, with its protective effect also apparent in susceptible populations like females and non-smokers. NEPA utilization markedly reduced both the incidence and severity of PONV in patients undergoing VATS radical resection of lung cancer, serving as an independent protective factor in mitigating PONV risk post-surgery.

Simple SummaryOral ondansetron is commonly prescribed to treat nausea and vomiting in dogs, but no studies have evaluated how well it is absorbed in clinical patients after oral administration. The objective of this study was to evaluate how well oral ondansetron is absorbed in a population of client-owned dogs with naturally occurring nausea. Twenty-four dogs were randomly assigned to receive one of the following doses of oral ondansetron, which are all within the currently recommended dose range: 0.5 mg/kg q8h, 0.5 mg/kg q12h, 1 mg/kg q8h, and 1 mg/kg q12h. Blood samples were collected for ondansetron measurement at various time points after administration of the first dose of ondansetron, and nausea scores were recorded. Ondansetron blood concentrations averaged over an 8 h time period were not significantly different between dose groups. The mean nausea scores at baseline were similar among all groups and decreased over time. Blood ondansetron concentrations were below the limit of detection in 44% (32/72) of all samples collected and were not detected at any timepoint in 25% (6/24) of the dogs. These results raise the concern that orally administered ondansetron at the current recommended dosages may not be absorbed into the bloodstream effectively.The purpose of this study was to evaluate plasma ondansetron (OND) concentrations in a population of dogs with naturally occurring nausea after oral OND administration. Twenty-four dogs were randomly assigned to receive one of the following doses of oral OND: 0.5 mg/kg q8h, 0.5 mg/kg q12h, 1 mg/kg q8h, or 1 mg/kg q12h. Blood samples for plasma OND measurements were collected at baseline and 2, 4, and 8 h after administration of the first dose of OND. OND concentrations averaged over an 8 h time period were not significantly different between dose groups (0.5 mg/kg group: median 8.5 ng/mL [range 1–96.8 ng/mL], 1 mg/kg group: median 7.4 ng/mL [range 1–278.7 ng/mL]). The mean maximum concentrations in the 0.5 mg/kg and 1 mg/kg groups were 35.8 ± 49.0 ng/mL and 63.3 ± 121.1 ng/mL, respectively. OND concentrations were below the lower limit of quantification (LLOQ) in 50% (18/36) of samples in the 0.5 mg/kg groups and 39% (14/36) of samples in the 1 mg/kg groups. Six dogs (6/24, 25%) did not have OND detected at any time. The mean nausea scores at baseline were similar amongst all groups and decreased over time. The bioavailability of oral OND appears to be poor. Despite low plasma OND concentrations, nausea scores improved over time.

Background: Chemotherapy-Induced Nausea and Vomiting (CINV) seriously affect cancer patients both physically and emotionally, therefore compromising their quality of life and maybe discouraging more treatment. The several kinds of CINV need for varied treatment schedules, usually involving corticosteroids, 5-HT3 receptor antagonist, and NK1 receptor antagonist. Methods: 150 pregnant women with non-small cell Lung Cancer were divided into Five groups: 1st group administer Ondansetron (OND); 2nd group administered Dexamethasone (Dex); 3rd group administered Metoclopramide (Met); 4th group on combination OND plus Dex and 5th group on Aprepitant plus Dexamethasone (Apr+Dex). the main objective was to assess the percentage of patients experiencing total CINV within each group. Results: Of the 150 women, 71 (44%) received MEC and 90 (56%) received HEC. The 4th group showed 60% Complete Control, 13% Complete Protection, and 27% Complete Response which consider better results and remarkable degree of protection as compared with other groups. 1st and 2nd groups showed non-significant difference (p&gt;0.05). Conclusion: The results of the study led to guidelines for the use of serotonin and corticosteroids to prevent CINV in patients with NSCLC undergoing chemotherapy.

Sepsis is a life-threatening disease with high morbidity and mortality, characterized by an inadequate systemic immune response to an initial stimulus. Whether the use of ondansetron (OND) during intensive care unit (ICU) stay is associated with the prognosis of sepsis patients remains unclear. Critically ill patients with sepsis were extracted from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. Multivariate logistic regression and Cox regression analyses were used to explore the association between OND use and clinical outcomes after adjusting for confounders. Kaplan-Meier survival curve was used for survival analysis. Propensity score matching (PSM) and subgroup analysis were performed to further confirm the results. The OND-medication group showed reduced in-hospital mortality, 28-day and 90-day mortalities. The OR for in-hospital mortality was 0.80 (0.64-0.99) and HRs for 28-day mortality and 90-day mortality were 0.77 (0.64-0.92) and 0.83 (0.70-0.98), respectively. After PSM, the clinical outcomes remained consistent. In-hospital mortality was lower in the OND-medication group (28.1% vs. 35.8%, P= 0.044), as well as 28-day mortality (23.4% vs. 32.1%, P=0.022) and 90-day mortality (27.4% vs. 35.8%, P=0.035). The protective effect of OND in sepsis patients was relatively robust, independent of age, septic shock, vasopressin and mechanical ventilation. Additionally, the OND users had longer lengths of stay in ICU (6.9(3.1-13.2) vs. 5.1(2.5-11.0), P = 0.026) while no statistical differences were found in lengths of stay in hospital (P = 0.333). OND exposure might be associated with lower in-hospital, 28-day, and 90-day mortality rates in critically ill patients with sepsis. This study indicated that OND might help improve the prognosis of patients with sepsis.

Quercetin (QUA), a flavonoid compound, is ubiquitously found in plants and has demonstrated a diverse range of biological activities. The primary objective of the current study is to assess the potential antiemetic properties of QUA using an in vivo and in silico approach. In this experiment, 4-day-old chicks were purchased to induce emesis by orally administering copper sulfate pentahydrate (CuSO4·5H2O) at a dose of 50 mg/kg (orally). Domperidone (DOM) (6 mg/kg), Hyoscine (HYS) (21 mg/kg), and Ondansetron (OND) (5 mg/kg) were treated as positive controls (PCs), and distilled water and a trace amount of Tween 80 mixture was employed as a negative control (NC). QUA was given orally at two distinct doses (25 and 50 mg/kg). Additionally, QUA (50 mg/kg) and PCs were administered separately or in combination to assess their antagonistic or synergistic effects on the chicks. The binding affinity of QUA and referral ligands towards the serotonin receptor (5HT3), dopamine receptors (D2 and D3), and muscarinic acetylcholine receptors (M1–M5) were estimated, and ligand–receptor interactions were visualized through various computational tools. In vivo findings indicate that QUA (25 and 50 mg/kg) has a significant effect on reducing the number of retches (16.50 ± 4.65 and 10.00 ± 4.19 times) and increasing the chick latency period (59.25 ± 4.75 and 94.25 ± 4.01 s), respectively. Additionally, QUA (50 mg/kg) in combination with Domperidone and Ondansetron exhibited superior antiemetic effects, reducing the number of retches and increasing the onset of emesis-inducing time. Furthermore, it is worth noting that QUA exhibited the strongest binding affinity against the D2 receptor with a value of −9.7 kcal/mol through the formation of hydrogen and hydrophobic bonds. In summary, the study found that QUA exhibited antiemetic activity in chicks, potentially by interacting with the D2 receptor pathway.

Antiemetic effects of sclareol, possibly through 5-HT3 and D2 receptor interaction pathways: In-vivo and in-silico studies

Ondansetron and AS19 attenuate morphine tolerance by modulating serotonin 5-HT3 and 5-HT7 receptor expressions in rat dorsal root ganglia

BackgroundPost-dural puncture headache (PDPH) is a major complication of neuraxial anesthesia. PDPH usually occurs after Caesarean section in obstetric patients. The efficacy of prophylactic pharmacological therapies remains controversial.MethodsSeven pharmacological therapies (aminophylline (AMP), dexamethasone, gabapentin/pregabalin (GBP/PGB), hydrocortisone, magnesium, ondansetron (OND), and propofol (PPF)), were studied in this Bayesian network meta-analysis. The primary outcome was the cumulative incidence of PDPH within 7 days. Secondary outcomes included the incidence of PDPH at 24 and 48 h postoperatively, the severity of headache in PDPH patients (24, 48, and 72 h postoperatively), and postoperative nausea and vomiting (PONV).ResultsTwenty-two randomized controlled trials with 4,921 pregnant women (2,723 parturients received prophylactic pharmacological therapies) were included. The analyses demonstrated that PPF, OND, and AMP were efficient in decreasing the cumulative incidence of PDPH during the follow-up period compared to the placebo group (OR = 0.19, 95% CI: 0.05 to 0.70; OR = 0.37, 95% CI: 0.16 to 0.87; OR = 0.40, 95% CI: 0.18 to 0.84, respectively). PPF and OND had the lower incidence of PONV compared to the placebo group (OR = 0.07, 95% CI: 0.01 to 0.30; and OR = 0.12, 95% CI: 0.02 to 0.63). No significant difference in other outcomes was found among different therapies.ConclusionsBased on available data, PPF, OND, and AMP may have better efficacy in decreasing the incidence of PDPH compared to the placebo group. No significant side effects were revealed. Better-designed studies are requested to verify these conclusions.

BACKGROUND: Postoperative nausea and vomiting (PONV) are common unpleasant adverse effects after surgery. The incidence of PONV in pediatric patients is often twice as high as in adults. OBJECTIVES: This study aimed to evaluate the effects of dexmedetomidine, dexamethasone, and ondansetron for preventing PONV in children undergoing dental rehabilitation surgery. STUDY DESIGN: A prospective, randomized controlled clinical trial. SETTING: Sharurah Armed Forces Hospital, Ministry of Defense Medical Services, Saudi Arabia. METHODS: One hundred patients (6-12 years old) scheduled for dental rehabilitation were included. Patients were randomly allocated into 4 groups (25 each) to receive either 0.15 mg/kg dexamethasone (DEX), 0.05 mg/kg ondansetron (OND), 0.3 microgram/kg dexmedetomidine (DEXMED), or normal saline (control[CONT]) in DEX, OND, DEXMED or CONT groups, respectively, via infusion after induction of anesthesia. The primary outcome was a PONV incident in the first 24 hours. Secondary outcomes were: granisetron doses during 24 hours postoperative, Paediatric Anaesthesia Emergence Delirium (PAED) scale, Pediatric Objective Pain Scale (POPS) for 4 hours postoperatively, and complications in the first 24 hours. RESULTS: The reduction of PONV and the overall number of patients who developed PONV was statistically significant in the DEXMED group compared to the CONT group (P = 0.041). However, the DEXMED group was higher compared to the DEX and OND groups but not statistically significant. Granisetron requirements and doses were statistically significantly lower in the DEXMED group than in the CONT group. PAED and POPS scores were much better in the DEXMED group than in the other groups with a statistically significant difference in most of the time measurements. LIMITATION: Optimal dexmedetomidine dose for better effect on PONV without affecting hemodynamic stability requires more studies. CONCLUSION: Dexmedetomidine is effective in reducing PONV in children undergoing dental rehabilitation with better sedative and analgesic scores as compared to the control group. KEY WORDS: Dexmedetomidine, dexamethasone, dental rehabilitation, ondansetron, postoperative nausea and vomiting

Background: Patients with myocardial infarction (MI) in intensive care units (ICU) are at high risk of death. Whether treatment with ondansetron (OND) at an early stage plays a protective role in critically ill patients with MI and its underlying mechanism remains unclear. Methods: A total of 4486 patients with MI were enrolled in the study cohort from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database and divided into OND-medication groups or not. Propensity score matching (PSM) and regression analysis were performed to investigate the effect of OND on patients, accompanied by sensitivity analysis to evaluate the robustness of the results. Integrated with causal mediation analysis (CMA), we investigated the potential causal pathway mediated by the palate-to-lymphocyte ratio (PLR) between early OND treatment and clinical outcomes. Results: Among patients with MI, 976 of them were treated with OND at the early stage while 3510 patients were not. The all-cause in-hospital mortality rate was significantly lower in the OND-medication group (5.6% vs 7.7%), accompanied by lower 28-day mortality (7.8% vs 11.3%) and 90-day mortality (9.2% vs 13.1%) rates. PSM analysis further confirmed the results for in-hospital mortality (5.7% vs 8.0%), 28-day mortality (7.8% vs 10.8%), and 90-day mortality (9.2% vs 12.5%). After adjusting for confounders, multivariate logistic regression analysis revealed that OND was associated with decreased in-hospital mortality (OR = 0.67, 95% CI: 0.49-0.91), and Cox regression confirmed the results for 28-day mortality and 90-day mortality with HR = 0.71 and 0.73, respectively. Most importantly, CMA demonstrated that the protective effect of OND on patients with MI was mediated by its anti-inflammatory effect through the regulation of PLR. Conclusion: Early use of OND in critically ill patients with MI may exert protective effects by reducing in-hospital mortality and 28- and 90-day mortality. The beneficial effects of OND on these patients were exerted through anti-inflammatory effects, at least in part.

IntroductionPost-operative nausea and vomiting (PONV) is a common problem after sleeve gastrectomy. In recent years, following the increase in the number of such operations, special attention has been paid to preventing PONV. Additionally, several prophylaxis methods have been developed, including enhanced recovery after surgery (ERAS) and preventive antiemetics. Nevertheless, PONV has not been completely eliminated, and the clinicians are trying to reduce the incidence of PONV yet.MethodsAfter successful ERAS implementation, patients were divided into five groups, including control and experimental groups. Metoclopramide (MA), ondansetron (OA), granisetron (GA), and a combination of metoclopramide and ondansetron (MO) were used as antiemetics for each group. The frequency of PONV during the first and second days of admission was recorded using a subjective PONV scale.ResultsA total of 130 patients were enrolled in this study. The MO group showed a lower incidence of PONV (46.1%) compared to the control group (53.8%) and other groups. Furthermore, the MO group did not require rescue antiemetics, however, one-third of control cases used rescue antiemetics (0 vs. 34%).ConclusionUsing the combination of metoclopramide and ondansetron is recommended as the antiemetic regimen for the reduction of PONV after sleeve gastrectomy. This combination is more helpful when implemented alongside ERAS protocols.

The experimental design extracts valuable information about the main effects and interactions from the least number of experiments. The current work constructs a solid-state sensor for selective assay of Ondansetron (OND) in pharmaceutical dosage form and plasma samples. During optimization, the Design Expert® statistical package constructed a custom design of 15 sensors with different recipes. We fed the software with the experimentally observed performance parameters for each sensor (slope, LOQ, correlation coefficient, and selectivity coefficient for sodium ions). The computer software analyzed the results to construct a prediction model for each response. The desirability function was adjusted to optimize the Nernstian slope, minimize the LOQ and selectivity coefficients, and maximize the correlation coefficient (r). The practical responses of the optimized sensor were close to those predicted by the model (slope = 60.23 mV/decade slope, LOQ = 9.09 × 10–6 M, r = 0.999, sodium selectivity coefficient = 1.09 × 10−3). The sensor successfully recovered OND spiked to tablets and human plasma samples with mean percentage recoveries of 100.01 ± 1.082 and 98.26 ± 2.227, respectively. Results were statistically comparable to those obtained by the reference chromatographic method. The validated potentiometric method can be used for fast and direct therapeutic drug monitoring of OND co-administered with chemotherapeutic drugs in plasma samples.